Congratulations to these 16 Millard North seniors for becoming National Merit Semifinalists.

Very excited to co-lead the new Cancer Prevention and Control Program with Dr. Peters UNMC College of Public Health

Congratulations Harshraj! Well deserved!!

Outcomes for patients treated via teleoncology at remote sites were similar to those at Omaha, suggesting effective oncology care, including systemic therapy, can be delivered remotely to improve access. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert Samia Asif Mridula Krishnan Apar Kishor Ganti

Outcomes following off‐site remote systemic cancer therapy administration - Arnold - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance The CALGB 30610 trial's quality-of-life substudy (CALGB 70702) compared once-daily and twice-daily thoracic radiotherapy (TRT) in patients with limited-stage small cell

Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance - Ganti - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/full/10.10…

Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance - Ganti - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/full/10.10…

🇮🇳 Gukesh D is the YOUNGEST WORLD CHAMPION in history! 🔥 👏

ICYMI: How does lung adenocarcinoma evade the immune system? This issue’s cover features work by Imay Lakshmanan & team showing aberrant sialylation promotes immune evasion & tumor angiogenesis in non–small cell lung cancer: jci.org/articles/view/… Imay Lakshmanan

Honored/humbled to be inducted as Fellow of ASCO (FASCO) along with many stellar colleagues/friends! United in the mission vs cancer Vamsi Velcheti, MD MBA FASCO Jason Westin, MD FACP FASCO Sandip Patel MD FASCO H. Jack West, MD, FASCO Lucky Lara Lynn Schuchter Julie Gralow Clifford Hudis Eric J. Small, MD, FASCO Fred Hutch Cancer Center Dr. Tom Lynch

Dr. Pasi Janne at #ASCO25 with update on KRYSTAL7: phase II study of first line adagrasib plus pembrolizumab for #KRAS G12C NSCLC. RR 44% (61% for PDL1 high). mDOR 26.3m, PFS 11m (27.7m for PDL1 high), OS 18.3m. 17% had to stop pembro for TRAE.

.Marcelo Corassa, MD. beautifully discusses EGFR/HER2 ex20ins development. Puts zipalertib data in context: similar ORRs. Tox of amivantamab is difficult & better for zipa. Suggests start with TKI and move to ami 2nd. In HER2, AE profile suggests TKI 1st may be preferable #ASCO25

Zipalertinib for EGFR exon20ins positive NSCLC- with a somewhat modest 40% RR but reasonable durability/noted CNS activity and a favorable AE profile- should zipalertinib be on the zipline for FDA approval? More options would certainly be welcome for our patients! Helena Yu

Wonderful presentation by Ticiana Batista (Leal) on “Getting right out of the gate”- ultimately what wins the horse race of selecting optimal frontline therapy for pts with st4 NSCLC will have to be BOTH efficacy AND long-term relevance Terrific job- Kentucky derby hat off! #ASCO25

SACHI; savo+osi vs chemo post TKI with FISH detected MET amp; Xover allowed in standard arm; modest benefits but chemo free #ASCO25

The first ever reception hosted by UNMC Buffett Cancer Center! Missing Julie Vose Chandra Are Joshua Mammen MD PhD from the picture.

Immunotherapy time of day study; RANDOMISED; 1500hr cut off; massive PFS benefit ; massive OS benefit. #ASCO25 BTOG #LCSM

CM816 final OS at 5yr: HR=0.72, 65 vs 55% OS rate, significant Benefit consistent across stage and more for PDL1+; arguable benefit in PDL1 neg pCR: 95% alive & 88% EFS at 5yr An established standard confirmed. Questions benefit for perioperative Tx Patrick Forde #ASCO25

Robust OS benefit overall from just 3 rounds of neoadj chemo-IO for resectable st 1b-3a NSCLC with unprecedented OS for pts reaching a pathCR (95% OS at 5 yrs- i am 100% this is just stunning and practice-guiding!) I’d say this is an excellent Forde model many of our patients